Today the Centers for Medicare & Medicaid Services (CMS) issued
a final rule with comment to implement the Medicaid drug rebate
provisions in the Affordable Care Act. The final regulation addresses
key areas of Medicaid drug reimbursement and changes made to the
Medicaid Drug Rebate Program by the Affordable Care Act. Among other
things, this final rule ensures federal and state savings on Medicaid drug
costs, establishes the long term framework for implementation of the
Medicaid drug rebate pro with gram, and creates a more fair reimbursement
system for Medicaid programs and pharmacies. In this final rule we also
solicit additional comments on the definition of line extension drugs and
the treatment of new formulations that we may consider addressing in
future rule making.
For more information, including summaries of key provisions of the final rule,
visit the Covered Outpatient Drugs Policy page on Medicaid.gov.